Esperion (ESPR) AI Stock Analysis

• Market Cap: $411.31M
• Dividend Yield: N/A
• Average Volume (3M): 5.44M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.82
• Revenue Growth: -3.48%
• EPS Growth: 36.57%
• Country: US
• Employees: 304
• Sector: Healthcare
• Sector Strength: 53
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.02
• Shares Outstanding: 201,622,820
• 10 Day Avg. Volume: 5,306,825
• 30 Day Avg. Volume: 5,444,731
• PEG Ratio: 0.09
• Price to Book (P/B): -1.06
• Price to Sales (P/S): 1.24
• P/FCF Ratio: -17.18
• Enterprise Value/Market Cap: 1.72
• Enterprise Value/Revenue: 2.72
• Enterprise Value/Gross Profit: 4.17
• Enterprise Value/Ebitda: -7.99
• 1Y Price Target: $6.10
• Price Target Upside: 186.38% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 60 Neutral
• Price Target: $2.00 ▼(-6.10% Downside)

Esperion's overall stock score is driven by strong technical momentum and positive earnings call highlights. However, financial performance and valuation challenges, including negative equity and ongoing losses, weigh heavily on the score. Corporate events provide some positive sentiment, but the financial instability remains a significant concern.

Positive Factors

Earnings

Esperion announced financial results that showed a significantly better EPS than both the company's and consensus estimates, indicating strong financial performance.

Product Development

The development of two triple combination products underway in the U.S. provides potential for significant life-cycle extension and patent protection.

Strategic Partnerships

Esperion announced a license and distribution agreement with HLS Therapeutics for the commercialization of NEXLETOL and NEXLIZET in Canada.

Negative Factors

Market Competition

Esperion is making strides to position BDA as the drug of choice over statins and PCSK9 inhibitors, which is expected to drive continued accelerated growth for the company’s commercial drug.

Sales Growth Requirements

≥10%Q/Q Nexletol/Nexlizet sales growth will likely be required to meet current 2025 Street sales consensus of $170MM to provide confidence in the franchise's growth potential and profitability timelines.

Esperion Business Overview & Revenue Model

Company Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

How the Company Makes Money

Esperion generates revenue primarily through the sale of its pharmaceutical products, particularly bempedoic acid, which is marketed under the brand name Nexletol. The company earns revenue by selling these products to healthcare providers and pharmacies, which in turn sell them to patients. Additionally, Esperion may receive royalties and milestone payments from partnerships and collaborations with larger pharmaceutical companies that have been established to enhance distribution and marketing efforts. Such partnerships can also facilitate access to broader markets and boost sales. Furthermore, the company may benefit from government and private health insurance reimbursements that cover the cost of its therapies, contributing significantly to its overall revenue.

Esperion Financial Statement Overview

Summary

Esperion demonstrates strong revenue growth but faces significant challenges with profitability and financial stability. Negative equity and high leverage are concerning, alongside persistent negative cash flow despite some improvements.

Income Statement

Esperion has shown significant revenue growth from 2023 to 2024, with a Revenue Growth Rate of 185.6%. However, the company is still facing challenges with profitability as indicated by the negative Net Profit Margin of -15.6% in 2024. The Gross Profit Margin improved to 79.3%, but the negative EBIT and EBITDA margins reflect ongoing operational challenges.

Balance Sheet

The balance sheet reveals a concerning negative Stockholders' Equity of -$388.7 million, indicating financial instability. The Debt-to-Equity Ratio is not calculable due to negative equity, highlighting high leverage. The Equity Ratio is also negative, suggesting that liabilities exceed assets, which poses a significant risk.

Cash Flow

Esperion's cash flow situation is challenging, with a negative Free Cash Flow of -$23.97 million in 2024. The Operating Cash Flow to Net Income Ratio is negative, indicating cash flow issues relative to net losses. However, the company has managed to reduce its negative Free Cash Flow compared to previous years, showing some improvement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	259.57M	332.31M	116.33M	75.47M	78.45M	227.55M
Gross Profit	169.51M	263.71M	73.07M	48.51M	64.23M	225.16M
EBITDA	-88.47M	7.57M	-150.11M	-176.35M	-222.14M	-120.33M
Net Income	-153.22M	-51.74M	-209.25M	-287.82M	-318.82M	-166.19M
Balance Sheet
Total Assets	324.03M	343.82M	205.80M	247.94M	381.59M	353.26M
Cash, Cash Equivalents and Short-Term Investments	114.63M	144.76M	82.25M	124.78M	208.89M	304.96M
Total Debt	297.78M	591.21M	540.95M	260.95M	260.20M	185.41M
Total Liabilities	750.24M	732.54M	660.79M	571.72M	578.53M	449.39M
Stockholders Equity	-426.21M	-388.72M	-454.99M	-1.34B	-1.11B	-838.82M
Cash Flow
Free Cash Flow	-100.35M	-23.97M	-135.49M	-174.83M	-263.81M	-98.55M
Operating Cash Flow	-100.11M	-23.65M	-135.49M	-174.83M	-263.81M	-85.18M
Investing Cash Flow	-244.00K	-317.00K	42.50M	8.10M	-50.48M	21.36M
Financing Cash Flow	-11.62M	86.48M	50.46M	32.61M	268.22M	201.72M

Esperion Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.13
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ESPR, the sentiment is Positive. The current price of 2.13 is above the 20-day moving average (MA) of 1.78, above the 50-day MA of 1.40, and above the 200-day MA of 1.66, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 72.34 is Negative, neither overbought nor oversold. The STOCH value of 76.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ESPR.

Esperion Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EBS	67 Neutral	$490.30M	3.77	30.24%	―	-22.74%	―
ESPR	60 Neutral	$411.31M	―	23.44%	―	-3.48%	36.57%
Sector *	57 Neutral	£5.42B	4.88	-44.55%	2.27%	28.89%	-10.08%
DERM	55 Neutral	$172.35M	―	-57.22%	―	-27.40%	-475.41%
AQST	54 Neutral	$465.75M	―	77.48%	―	-24.38%	-94.72%
LFCR	50 Neutral	$271.21M	―	-76.41%	―	0.47%	-430.88%
IRWD	46 Neutral	$173.80M	85.74	-8.02%	―	-22.98%	-173.28%

Esperion Corporate Events

Esperion Expands Board with New Appointment

On July 1, 2025, Esperion announced the appointment of Craig Thompson, CEO of Cerevance, to its Board of Directors, expanding the board to eight members. Thompson’s extensive experience in biopharmaceutical leadership is expected to enhance Esperion’s strategic direction as it continues to innovate in cardiovascular and cardiometabolic drug development, potentially impacting its market position and stakeholder interests.

Esperion Gains Strong Shareholder Support at Annual Meeting

On May 29, 2025, Esperion held its Annual Meeting where stockholders voted on several key proposals. These included the election of two Class III director nominees, approval of executive compensation, ratification of Ernst & Young LLP as the independent accounting firm for 2025, and an amendment to increase shares under the 2022 Plan. All proposals were approved, indicating strong shareholder support for the company’s strategic decisions.